Holen Sie sich die Stockscreener-App
20.92
2.80%
0.57
Handel nachbörslich:
20.94
0.02
+0.10%
Schlusskurs vom Vortag:
$20.35
Offen:
$20.35
24-Stunden-Volumen:
24,723
Relative Volume:
0.26
Marktkapitalisierung:
$1.13B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-123.41M
KGV:
-9.7848
EPS:
-2.138
Netto-Cashflow:
$-106.93M
1W Leistung:
-1.55%
1M Leistung:
-1.32%
6M Leistung:
+2.80%
1J Leistung:
+29.54%
1-Tages-Spanne:
$20.20
$20.98
1-Wochen-Bereich:
$19.78
$21.38
52-Wochen-Spanne:
$15.00
$33.00
Pharvaris Nv Stock (PHVS) Company Profile
Vergleichen Sie PHVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| PHVS | 20.92 | 1.13B | 0 | -123.41M | -106.93M | -2.138 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-25 | Eingeleitet | Wedbush | Outperform |
| 2023-08-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Eingeleitet | Bryan Garnier | Buy |
| 2022-09-13 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2022-08-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
(PHVS) Long Term Investment Analysis - Stock Traders Daily
Pharvaris Reports 93% HAE Attack Reduction in Trial Data, Plans Phase 3 Study | PHVS Stock News - StockTitan
Pharvaris to Present HAE Treatment Progress at Guggenheim Healthcare Conference | PHVS Stock News - StockTitan
Trend Tracker for (PHVS) - Stock Traders Daily
Axonis Therapeutics Announces $115 Million Series A Financing - Financial Times
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting - StockTitan
(PHVS) Proactive Strategies - Stock Traders Daily
Pharvaris (PHVS) Shares Cross Above 200 DMA - Nasdaq
PHVSPharvaris N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at ... - The Hastings Tribune
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings - StockTitan
Pharvaris to Host Virtual Investor Event on October 23, 2024 - StockTitan
(PHVS) Investment Report - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Gap DownShould You Sell? - MarketBeat
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at - The Bakersfield Californian
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop - StockTitan
Novo Holdings A S Buys 556,970 Shares of Pharvaris (NASDAQ:PHVS) - MarketBeat
Pharvaris N.V.'s SWOT analysis: promising HAE drug boosts stock outlook - Investing.com India
Pharvaris CBO Resigns, Team Absorbs Duties - TipRanks
(PHVS) Technical Data - Stock Traders Daily
Hereditary Angioedema Therapeutics Global Market Report Explores 2024: Size Forecast and Growth Prospects 2033 - WhaTech
Pharvaris (NASDAQ:PHVS) Shares Gap Down to $21.09 - MarketBeat
EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma - sharewise
Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Paradise, NV – Injuries Reported in Vehicle Accident on I-215 W near Las Vegas Blvd Onramp - Local Accident Reports
Las Vegas, NV – Accident on I-215 E near Windmill Ln Results in Injuries - Local Accident Reports
North Las Vegas Man Charged in Fatal Hit-and-Run After Allegedly Fleeing Accident Scene - Hoodline
Paradise, NV – Vehicle Accident at I-215 E and Las Vegas Blvd - Local Accident Reports
Las Vegas, NV – Vehicle Accident at CC215 S and W Sunset Rd Causes Injuries - Local Accident Reports
Highway reopens outside Las Vegas after crash, fire in semi hauling lithium batteries - KRNV
Road closures persist after trucks carrying wood and batteries collide - News3LV
Appeal over identifying invasive hornets in Jersey - BBC.com
Hwy 95 closes in Nye County after crash involving truck carrying lithium batteries - Audacy
1 person transported to hospital after Henderson crash involving bicyclist - Fox 5 Las Vegas
1 hospitalized in Henderson crash involving bicyclistKLAS - KLAS - 8 News Now
Oregon man dies northwest of Las Vegas Valley, state police say - Fox 5 Las Vegas
1 person taken to hospital after crash involving car, bicyclist in Henderson - News3LV
Rep. Steven Horsford releases updated campaign ad after LVPPA concerns - KTNV 13 Action News Las Vegas
Silver Springs man killed in crash on U.S. 50A & 6th Street in Fernley - KTVN
Las Vegas, NV – Collision at CC215 S & W Flamingo Rd Results in Injuries - Local Accident Reports
Pharvaris (NASDAQ:PHVS) Shares Gap Up After Analyst Upgrade - MarketBeat
Pharvaris stock outlook strengthened with price target increase, Outperform rating reiterated by Oppenheimer - Investing.com UK
(PHVS) Technical Pivots with Risk Controls - Stock Traders Daily
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and ... - The Bakersfield Californian
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant - StockTitan
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024 - StockTitan
Pharvaris Presents Data at the Bradykinin Symposium 2024 - StockTitan
Pharvaris to Present at SVB Securities Global Biopharma Conference - Yahoo Finance UK
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium - Yahoo Finance UK
Pharvaris (NASDAQ:PHVS) Shares Gap Down to $19.08 - MarketBeat
Finanzdaten der Pharvaris Nv-Aktie (PHVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):